ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 2574 • ACR Convergence 2024

    Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children

    Mariia Pavlenko1, Ilaria Maccora2, Mekibib Altaye3, hermine brunner4, Alexandra Duell3, Megan Quinlan-Waters3, Alyssa Sproles1, Sherry Thornton5, Virginia Miraldi Utz3 and sheila Angeles-Han6, 1Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 2?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 5Cincinnati Children's Hospital, Cincinnati, 6Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …
  • Abstract Number: 0047 • ACR Convergence 2024

    Asthma Is Associated with Increased Serum IgA Antibodies to Citrullinated Peptide Antigenscompared to Healthy Controlsin Discovery and Validation Cohorts

    Drayton Rorah1, Linh Ngo2 and Scott Matson3, 1University of Kansas, Internal Medicine, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, 3University of Kansas, Kansas City, MO

    Background/Purpose: The connection between airway inflammation as seen in patients with asthma and rheumatoid arthritis (RA) has been suggested by previous epidemiologic studies. For instance,…
  • Abstract Number: 0271 • ACR Convergence 2024

    Intercritical Gout Represents a Systemic Inflammatory State

    Tanner Ourada1, Austin Wheeler2, Michael Duryee2, Bryant England2, Richard Reynolds3, James O'Dell2, Jeff Newcomb2, Michael Pillinger4, Robert Terkeltaub5, Ryan Ferguson6, Mary Brophy6, Tony Merriman7 and Ted Mikuls2, 1University of Nebraska-Medical Center: College of Medicine, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, AL, 4New York University Grossman School of Medicine, New York,, NY, 5Retired, San Diego, CA, 6Veterans Affairs, Boston, MA, 7University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
  • Abstract Number: 0572 • ACR Convergence 2024

    Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

    Patricia Remalante-Rayco1, Emmanuel Baja2, Zeynep Baskurt3, Tina Chim4, Robert Inman5, Leonila Dans6 and Nigil Haroon7, 1Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, 3Department of Biostatistics, University Health Network, Toronto, Canada, 4Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 5University Health Network, Toronto, ON, Canada, 6Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
  • Abstract Number: 0882 • ACR Convergence 2024

    Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes

    Jiří Vencovský1, Alexandra Goriounova2, Lisa McConnachie2 and Brendan Johnson2, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Priovant Therapeutics, Durham, NC

    Background/Purpose: Dermatomyositis (DM) is characterized by inflammatory and degenerative changes of skin and muscle and upregulation of Type I IFN-regulated gene and protein levels in…
  • Abstract Number: 1088 • ACR Convergence 2024

    Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout

    Cristina Rodríguez Alvear, Agustín Martínez Sanchís, Irene Calabuig Sais and Mariano Andrés, Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain

    Background/Purpose: Carotid atherosclerosis is prevalent in patients with gout. A prior cross-sectional study at our hospital demonstrated an association between tophi and positive Power Doppler…
  • Abstract Number: 1656 • ACR Convergence 2024

    Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis

    Katherine Escalera-Rivera, Jennifer Jonason and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Osteoarthritis (OA) is a complex disease involving pathological processes in joint tissues such as the cartilage and synovium. Cartilage is degraded by matrix metalloproteinases…
  • Abstract Number: 1959 • ACR Convergence 2024

    A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients

    ESPERANZA NAREDO1, Otto Olivas-Vergara2, Pablo E. Borges2, Sheila Recuero-Díaz2, Fernando Saraiva3, Joana Martinho3, Filipa Costa3, Catarina Tenazinha3, Margarida Monteiro3, Ana Teresa Melo3, Ana Rodriguez-García4, Carlos A. Guillén-Astete5, Boris A. Blanco-Cáceres4, Alina L. Boteanu4, Antonio Mera-Varela6, Eva Pérez Pampín6, Yolanda López Golán6, Cristina Campos Fernández7, Jorge Juan Fragío Gíl7, roxana gonzalez mazarío7, Juan José De Agustín8, Gustavo Añez Sturchio9, Luis Coronel Tarancon8, Esther Vicente-rabaneda10, Santos Castañeda10, Irene Llorente-Cubas10, Maria S. Stoenoiu11, NZEUSSEU TOUKAP Adrien12, Ilaria Padovano13, Helene Gouze13, Ariane Leboime13, Maxime Breban14, Jaqueline Uson15, Virginia Villaverde16, Martina Steiner17, Cristina Vergara Dangond17, Maria Beatriz Paredes Romero17, Santiago Muñoz Fernández18, Carolina Pérez-García19, Juan Antonio Meraz-Ostiz19, Stephanie Finzel20, Anna-Maria Kanne21, Aránzazu Mediero22, Carmen Herencia23, Gabriel Herrero-Beaumont24 and Raquel Largo22, 1Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 3Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 4Rheumatology Department. Ramón y Cajal University Hospital, Madrid, Spain, 5Rheumatology Department. Ramon y Cajal University Hospital, Madrid, Spain, 6Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 7Department of Rheumatology. Hospital General Universitario de Valencia, Valencia, Spain, 8Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, 9Department of Rheumatology. Hospital Arnau de Vilanova, Lleida, Spain, 10Hospital Universitario de La Princesa, Madrid, Spain, 11Cliniques Universitaires Saint-Luc, Brussels, Belgium, 12Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 13Departement of Rheumatology, Hopital Ambroise Paré, Boulogne-Billancourt, Spain, 14Departement of Rheumatology, Hopital Ambroise Paré, Departement of Rheumatology, Hopital Ambroise Paré, Spain, 15Department of Rheumatology, Hospital Universitario de Móstoles. University Rey Juan Carlos, Madrid, Spain, 16Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain, 17Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, 18Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, 19Department of Rheumatology, Hospital del Mar of Barcelona, Barcelona, Spain, 20Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, 21Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany, 22Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, 23Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, 24Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain

    Background/Purpose: To demonstrate non-inferiority of the response of musculoskeletal ultrasound (MSKUS)-assessed synovitis to baricitinib, alone and plus MTX vs. etanercept plus MTX in patients with…
  • Abstract Number: 2107 • ACR Convergence 2024

    Deep Immunophenotyping of Knee Osteoarthritis Patients Reveals Alterations in T Cell, Treg, and Monocyte Subpopulations

    Montana Barrett1, Gabby dyson2, Nicholas Hannebutt3, Aleksander Szymczak2, Cindy Miranda4 and Matlock Jeffries2, 1University of Oklahoma, Cement, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Spencer, OK, 4Oklahoma Medical Research Foundation, Yukon, OK

    Background/Purpose: Previous studies have suggested low-level chronic inflammation plays a key role in knee osteoarthritis (OA) development and progression, although attention has mostly been focused…
  • Abstract Number: 2583 • ACR Convergence 2024

    Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study

    Mikkel Ostergaard1, Walter Maksymowych2, Robert Lambert2, Mikael Boesen3, Guillermo J. Valenzuela4, Michael R. Bubb5, Olga Kubassova6, Xenofon Baraliakos7, Carlo Selmi8, Stephen Colgan9, Yuri Klyachkin10, Cynthia Deignan11, Zhenwei Zhou11 and Philip Mease12, 1Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 2University of Alberta, Edmonton, AB, Canada, 3Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 4Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 5University of Florida, Gainesville, FL, 6Image Analysis Group, Philadelphia, PA, 7Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 8Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, 9Amgen, Halton Hills, ON, Canada, 10Amgen, Lexington, KY, 11Amgen Inc., Thousand Oaks, CA, 12Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Apremilast is an oral phosphodiesterase-4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA). Although…
  • Abstract Number: L05 • ACR Convergence 2023

    DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis

    Guoqi Cai1, Graeme Jones2, Flavia Cicuttini3, Anita Wluka3, Yuanyuan Wang3, Catherine Hill4, Helen Keen5, Benny Antony2, barbara de Graaff2, Michael Thompson2, Tania Winzenberg2, Kathy Buttigieg2, Petr Otahal2 and Dawn Aitken2, 1School of Public Health, Anhui Medical University, Hefei, China, 2Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 3Monash University, Melbourne, Australia, 4The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, 5Fiona Stanley Hospital, Murdoch, Australia

    Background/Purpose: There is an unmet need for treatments of knee OA. Diacerein is recommended for alleviating pain in OA patients for its anti-inflammatory effect by…
  • Abstract Number: 0061 • ACR Convergence 2023

    Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases

    Marta Wlodarska1, Chad Van Huis2, Florian Hoss3, Rosana Meyer1, Xiaokang Lu2, Dominik Koelmel2, Brian Sanchez2, Chuck Lesch2, Alissa Telling2, Martin Minns1, Nneka Mbah2, Isabelle Lacan1, Robert Aversa1, Charles Lesburg1, Carmen Yu2, Stephen Soisson1, Natalie Dales1, Darryl Patrick1, Anthony Opipari2, Shifeng Pan4 and Luigi Franchi2, 1Odyssey Therapeutics, Boston, MA, 2Odyssey Therapeutics, Ann Arbor, MI, 3Odyssey Therapeutics, Frankfurt, Germany, 4Odyssey Therapeutics, San Diego, CA

    Background/Purpose: Receptor interacting protein kinase 2 (RIPK2) is a key signaling node for inflammation caused by peptidoglycan (PGN). In the intestine, RIPK2 integrates signaling originating…
  • Abstract Number: 0418 • ACR Convergence 2023

    Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis

    Edoardo Spolaore1, Edward DiCarlo2, Daniel Ramirez2, Melanie Smith2, Amit Lakhanpal2, Bella Mehta3, Laura Donlin2, Susan Goodman2 and Dana Orange4, 1HSS, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…
  • Abstract Number: 0875 • ACR Convergence 2023

    INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis

    Jung Gyu Park1, Yurim Lee1, Joonghoon Park2 and myungjin Kim3, 1Innovo Therapeutics Inc., Daejeon, South Korea, 2Institute of Green Bio Science and Technology, Seoul National University, Pyeongchang, South Korea, 3HLB bioStep Co. Ltd, Incheon, South Korea

    Background/Purpose: Osteoarthritis poses a substantial medical challenge, as the available treatments primarily target symptom relief and fail to effectively halt the progressive cartilage deterioration that…
  • Abstract Number: 1101 • ACR Convergence 2023

    Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

    Maria-Luisa Peral-Garrido1, Paula Boix-Navarro2, Silvia Gómez-Sabater3, Rocío Caño-Alameda3, Alejandra Bermúdez-García4, Teresa Lozano4, Ruth Sanchez-Ortiga4, Miguel Perdiguero4, Elena Caro-Martínez5, Carolina Ruiz-García6, Eliseo Pascual4, Rubén Francés2 and Mariano Andrés4, 1Vinalopó University Hospital, Novelda, Spain, 2Miguel Hernandez University, San Juan de Alicante, Spain, 3Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 4Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 5San Vicente Hospital-HACLE, San Vicente del Raspeig, Spain, 6Campoamor Health Centre, Alicante, Spain

    Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology